News und Analysen
EQS-News: Aurubis AG: Enabling tomorrow: Aurubis releases new Sustainability Report
EQS-News: Aurubis AG: Enabling tomorrow: Aurubis releases new Sustainability Report
![EQS-News: CANCOM: Financial year 2022 ends with record revenue in the fourth quarter. Dividend proposal of €1.00 per share and forecast 2023 published.: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24051/375px-PLAN._BUILT._PERFORM..png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBGdz09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--005550558ff6cd75315318300eba0697f03f1350/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/375px-PLAN_BUILT_PERFORM.png?locale=de)
EQS-News: CANCOM: Financial year 2022 ends with record revenue in the fourth quarter. Dividend proposal of €1.00 per share and forecast 2023 published.
EQS-News: CANCOM: Financial year 2022 ends with record revenue in the fourth quarter. Dividend proposal of €1.00 per share and forecast 2023 published.
![EQS-News: CANCOM: Financial year 2022 ends with record revenue in the fourth quarter. Dividend proposal of €1.00 per share and forecast 2023 published.: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24051/375px-PLAN._BUILT._PERFORM..png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBGdz09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--005550558ff6cd75315318300eba0697f03f1350/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/375px-PLAN_BUILT_PERFORM.png?locale=de)
EQS-News: CANCOM: Financial year 2022 ends with record revenue in the fourth quarter. Dividend proposal of €1.00 per share and forecast 2023 published.
EQS-News: CANCOM: Financial year 2022 ends with record revenue in the fourth quarter. Dividend proposal of €1.00 per share and forecast 2023 published.
EQS-News: SHOP APOTHEKE EUROPE and GALENICA enter into a strategic partnership and jointly establish the leading online pharmacy in Switzerland.
EQS-News: SHOP APOTHEKE EUROPE and GALENICA enter into a strategic partnership and jointly establish the leading online pharmacy in Switzerland.
EQS-Adhoc: SHOP APOTHEKE EUROPE N.V. and GALENICA AG enter into strategic partnership and establish a joint venture for the Swiss business; execution of capital increase.
EQS-Adhoc: SHOP APOTHEKE EUROPE N.V. and GALENICA AG enter into strategic partnership and establish a joint venture for the Swiss business; execution of capital increase.
EQS-Adhoc: United Internet with successful fiscal year 2022
EQS-Adhoc: United Internet with successful fiscal year 2022
EQS-Adhoc: United Internet with successful fiscal year 2022
EQS-Adhoc: United Internet with successful fiscal year 2022
EQS-Adhoc: 1&1 with successful fiscal year 2022
EQS-Adhoc: 1&1 with successful fiscal year 2022
EQS-Adhoc: 1&1 with successful fiscal year 2022
EQS-Adhoc: 1&1 with successful fiscal year 2022
![Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN042Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ae05d9a008178586e36a804ddc8db7301200475e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/5009664_Horizon_Logo_Full-Color_CMYK_M01_-281-29.jpg?locale=de)
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
![Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN042Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ae05d9a008178586e36a804ddc8db7301200475e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/5009664_Horizon_Logo_Full-Color_CMYK_M01_-281-29.jpg?locale=de)
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
![EQS-News: Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBMUT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--5ccaaee20e4dd47dccd2b888e74ce998199f16f5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Evotec_high_res_logo_-28blue_and_grey-29.jpg?locale=de)
EQS-News: Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership
EQS-News: Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership
![EQS-Adhoc: Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBMUT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--5ccaaee20e4dd47dccd2b888e74ce998199f16f5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Evotec_high_res_logo_-28blue_and_grey-29.jpg?locale=de)
EQS-Adhoc: Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership
EQS-Adhoc: Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership
EQS-News: Rational AG fiscal year 2022: sales revenues grow by 31 percent to break the one billion euro mark for the first time – significant increase in EBIT margin to 23.2 percent
EQS-News: Rational AG fiscal year 2022: sales revenues grow by 31 percent to break the one billion euro mark for the first time – significant increase in EBIT margin to 23.2 percent
![EQS-News: Evotec SE preliminary fiscal year 2022 results: 'Ahead of the curve' – very strong performance in a challenging year: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBMUT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--5ccaaee20e4dd47dccd2b888e74ce998199f16f5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Evotec_high_res_logo_-28blue_and_grey-29.jpg?locale=de)
EQS-News: Evotec SE preliminary fiscal year 2022 results: 'Ahead of the curve' – very strong performance in a challenging year
EQS-News: Evotec SE preliminary fiscal year 2022 results: 'Ahead of the curve' – very strong performance in a challenging year
![Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN042Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ae05d9a008178586e36a804ddc8db7301200475e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/5009664_Horizon_Logo_Full-Color_CMYK_M01_-281-29.jpg?locale=de)
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: KION Group and Li-Cycle Agree to Form Strategic Battery Recycling Partnership Focused on Circular Economy
EQS-News: KION Group and Li-Cycle Agree to Form Strategic Battery Recycling Partnership Focused on Circular Economy
EQS-Adhoc: VARTA AG: VARTA AG reaches agreement with banks on comprehensive restructuring concept
EQS-Adhoc: VARTA AG: VARTA AG reaches agreement with banks on comprehensive restructuring concept
EQS-Adhoc: VARTA AG: VARTA AG reaches agreement with banks on comprehensive restructuring concept
EQS-Adhoc: VARTA AG: VARTA AG reaches agreement with banks on comprehensive restructuring concept
EQS-News: MorphoSys AG: Repurchase of portion of outstanding convertible bonds due 2025 (ISIN DE000A3H2XW6)
EQS-News: MorphoSys AG: Repurchase of portion of outstanding convertible bonds due 2025 (ISIN DE000A3H2XW6)
EQS-News: MorphoSys AG: Repurchase of portion of outstanding convertible bonds due 2025 (ISIN DE000A3H2XW6)
EQS-News: MorphoSys AG: Repurchase of portion of outstanding convertible bonds due 2025 (ISIN DE000A3H2XW6)
EQS-News: freenet confirms 2022 preliminary results, dividend proposal of 1.68 euros and 2023 guidance
EQS-News: freenet confirms 2022 preliminary results, dividend proposal of 1.68 euros and 2023 guidance
EQS-News: freenet confirms 2022 preliminary results, dividend proposal of 1.68 euros and 2023 guidance
EQS-News: freenet confirms 2022 preliminary results, dividend proposal of 1.68 euros and 2023 guidance
![Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN042Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ae05d9a008178586e36a804ddc8db7301200475e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/5009664_Horizon_Logo_Full-Color_CMYK_M01_-281-29.jpg?locale=de)
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
![EQS-News: Evotec receives US$ 6.6 m grant for drug discovery in tuberculosis: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBMUT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--5ccaaee20e4dd47dccd2b888e74ce998199f16f5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Evotec_high_res_logo_-28blue_and_grey-29.jpg?locale=de)
EQS-News: Evotec receives US$ 6.6 m grant for drug discovery in tuberculosis
EQS-News: Evotec receives US$ 6.6 m grant for drug discovery in tuberculosis